Company / Free Cash Flow
TScan Therapeutics, Inc. Free Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$114.6M
FY2025
5-year range
-$114.6M / -$7.3M
FY2021-FY2025
Trend
-77.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$71M to -$115M over the past 2 years.
Based on SEC 10-K filings.
-$115M in FY2025.
Declined from -$71M to -$115M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow decreased 77.7% year-over-year.
- Peak free cash flow was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$114.6M | -77.7% |
| FY2024 | -$64.5M | +8.8% |
| FY2023 | -$70.7M | -20.7% |
| FY2022 | -$58.6M | -707.3% |
| FY2021 | -$7.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026